Biotoxin Illness and CIRS

Condition: Biotoxin Illness and CIRS  |  Category: Inflammation and Environmental Health  |  Reviewed by: Brian Lamkin, DO

What Is Biotoxin Illness and CIRS?

Chronic Inflammatory Response Syndrome (CIRS) is a multi-system, multi-symptom inflammatory illness caused by exposure to biotoxins in genetically susceptible individuals. The biotoxins most commonly implicated are produced by mold species (Stachybotrys, Aspergillus, Penicillium, Chaetomium) growing in water-damaged buildings, Borrelia burgdorferi and its co-infections (Lyme disease), and marine dinoflagellates (ciguatera, Pfiesteria). Approximately 25 percent of the population carries HLA-DR genotypes that prevent their immune systems from recognizing and clearing these biotoxins through normal antigen presentation pathways.

In these genetically susceptible individuals, biotoxins circulate continuously because they are never tagged for immune clearance. This triggers a chronic, self-perpetuating innate immune response that produces inflammatory cytokines, disrupts neuropeptide signaling (MSH, VIP, ADH), activates complement pathways (C4a), elevates matrix metalloproteinases (MMP-9), and dysregulates growth factors (TGF-beta 1, VEGF). The result is a multi-organ inflammatory illness that produces 37 or more symptoms spanning neurological, musculoskeletal, respiratory, gastrointestinal, cognitive, and hormonal systems simultaneously.

Why Biotoxin Illness and CIRS Matters

Common Symptoms of Biotoxin Illness and CIRS

Root Causes: A Functional Medicine Perspective

CIRS is not a condition with multiple possible causes. It is a defined pathophysiological sequence with a specific trigger (biotoxin exposure), a specific genetic predisposition (HLA-DR), and a specific inflammatory cascade that produces identifiable biomarker abnormalities.

HLA-DR Genetic Susceptibility

The HLA-DR gene complex encodes proteins on antigen-presenting cells that recognize and tag foreign substances for immune clearance. In approximately 25 percent of the population, HLA-DR variants produce proteins that cannot recognize biotoxin molecular structures. These individuals clear bacterial and viral pathogens normally but cannot clear the specific molecular structures produced by mold, Lyme, and dinoflagellate organisms. This is a genetic difference, not a deficiency of willpower or immune weakness.

The Biotoxin Pathway

In susceptible individuals, biotoxins bind to fat-soluble tissue sites and trigger chronic innate immune activation. The cytokines produced (IL-1, IL-6, TNF-alpha) increase vascular permeability and activate complement (C4a). MSH (alpha-melanocyte stimulating hormone) is depleted, removing the regulatory brake on inflammation and disrupting sleep, pain modulation, and antimicrobial peptide production. VIP (vasoactive intestinal peptide) declines, impairing pulmonary, GI, and immune function. The inflammatory markers MMP-9 and TGF-beta 1 rise, producing connective tissue degradation and immune dysregulation.

MARCoNS and Nasal Biofilm

Multiple Antibiotic Resistant Coagulase Negative Staphylococci (MARCoNS) colonize the deep nasal passages in the majority of CIRS patients. These organisms produce exotoxins that further deplete MSH, perpetuating the inflammatory cycle even after the biotoxin source is removed. MARCoNS eradication is a required step in the Shoemaker protocol before VIP can be initiated.

Environmental Source and Ongoing Exposure

The most common biotoxin source is mold growth in water-damaged buildings. Up to 50 percent of buildings in the United States have some degree of water damage. A susceptible individual living or working in a water-damaged building is exposed to a continuous biotoxin load that perpetuates the inflammatory cascade regardless of treatment. Source identification and removal is the non-negotiable first step.

Conventional vs Functional Medicine Approach

Key Labs to Evaluate

CIRS diagnosis requires a specific biomarker panel that is not part of standard medical evaluation. Standard labs including CBC, CMP, TSH, and autoimmune panels are typically normal in CIRS patients because the condition involves innate immune activation, not the adaptive immune pathways these tests measure.

How to Interpret These Labs Together

Common Patterns Seen in Patients

• The patient seen by 12 specialists with no diagnosis: Brain fog, joint pain, fatigue, shortness of breath, chronic sinus congestion, and unexplained thirst. Evaluated by neurology, rheumatology, pulmonology, ENT, endocrinology, and psychiatry. All standard labs normal. Diagnosed with depression and fibromyalgia. CIRS biomarker panel: MSH depleted, MMP-9 elevated, TGF-beta 1 elevated, C4a elevated, HLA-DR susceptible genotype. ERMI score of 8.4 in the home (above 2.0 threshold). Diagnosis: CIRS from water-damaged building exposure. Shoemaker protocol initiated.
• The patient who improved after moving but relapsed: Symptoms improved 40 percent after moving out of a water-damaged apartment. Residual symptoms attributed to "stress." MARCoNS positive on deep nasal culture, continuing to deplete MSH and perpetuate the inflammatory cycle. BEG spray eradication followed by cholestyramine binding produced symptom resolution that the move alone could not achieve because the nasal biofilm was maintaining the cascade.
• The child with declining school performance: Previously high-performing student with progressive cognitive decline, fatigue, and headaches over 18 months. Evaluated for ADHD, learning disabilities, and depression. Home had a hidden water leak for 2 years. HERTSMI-2 score positive. CIRS biomarkers confirmed. Environmental remediation plus cholestyramine restored cognitive function within 3 months.
• The Lyme patient who never recovers: Treated with multiple antibiotic courses for confirmed Lyme disease. Fatigue, cognitive dysfunction, and joint pain persist despite negative post-treatment Lyme testing. The Lyme biotoxins were never cleared because the patient carries HLA-DR genotype preventing biotoxin clearance. Cholestyramine binding of circulating Lyme biotoxins produced the improvement that additional antibiotics could not achieve.

Treatment and Optimization Strategy

The Shoemaker Protocol (Stepwise)

CIRS treatment follows a validated, sequential protocol. Steps must be performed in order because each builds on the foundation of the previous step. Skipping steps or performing them out of order produces incomplete results.

What Most Doctors Miss

• Standard labs do not detect CIRS: CBC, CMP, autoimmune panels, and allergy testing are normal in the majority of CIRS patients. The diagnosis requires a specific biomarker panel (MSH, VIP, MMP-9, TGF-beta 1, C4a, VEGF, ADH/osmolality) that standard practice does not order.
• Multi-system symptoms are fragmented across specialties: the neurological, musculoskeletal, respiratory, and cognitive symptoms are each evaluated by a different specialty, and the connecting pattern is never recognized as a single environmental illness.
• Mold illness is dismissed as illegitimate: despite validated biomarker protocols, published research, and clinical evidence, mold-related illness is not recognized by many providers, producing dismissal and psychiatric referral.
• Removing the patient from exposure is necessary but not sufficient: biotoxins continue to circulate in susceptible individuals after exposure ends because they cannot be cleared without binding therapy. Moving out of a moldy building improves but rarely resolves symptoms without cholestyramine binding.

When to Seek Medical Care

If you experience multi-system symptoms including brain fog, fatigue, joint pain, shortness of breath, chronic sinus congestion, and excessive thirst, particularly if symptoms began or worsened after exposure to a water-damaged building or after a Lyme disease diagnosis, CIRS evaluation is warranted. This is especially important if standard labs are normal and symptoms have been attributed to depression, fibromyalgia, or chronic fatigue syndrome without environmental investigation.

At The Lamkin Clinic, CIRS evaluation follows the Shoemaker protocol: HLA-DR genotyping, the full CIRS biomarker panel, VCS (Visual Contrast Sensitivity) testing, MARCoNS nasal culture, and environmental assessment guidance.

Recommended Testing

Frequently Asked Questions

How The Lamkin Clinic Approaches Biotoxin Illness and CIRS

At The Lamkin Clinic, CIRS evaluation follows the Shoemaker protocol: HLA-DR genotyping, the full CIRS biomarker panel (MSH, VIP, MMP-9, TGF-beta 1, C4a, VEGF, ADH/osmolality, ACTH/cortisol), VCS testing, MARCoNS nasal culture, and environmental assessment. Treatment is implemented as the validated stepwise protocol: source removal, cholestyramine binding, MARCoNS eradication, hormonal correction, and VIP restoration.

Related Conditions

Related Symptoms